Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
334M
-
Number of holders
-
264
-
Total 13F shares, excl. options
-
149M
-
Shares change
-
+8.38M
-
Total reported value, excl. options
-
$6.9B
-
Value change
-
+$437M
-
Put/Call ratio
-
0.69
-
Number of buys
-
127
-
Number of sells
-
-133
-
Price
-
$46.40
Significant Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) as of Q4 2020
322 filings reported holding IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock as of Q4 2020.
IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) has 264 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 149M shares
of 334M outstanding shares and own 44.49% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (15.3M shares), VANGUARD GROUP INC (11.9M shares), PERCEPTIVE ADVISORS LLC (9.17M shares), BlackRock Inc. (9M shares), FRANKLIN RESOURCES INC (8.93M shares), Avoro Capital Advisors LLC (7.5M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7.38M shares), ORBIMED ADVISORS LLC (6.65M shares), FARALLON CAPITAL MANAGEMENT LLC (6M shares), and WELLINGTON MANAGEMENT GROUP LLP (5.61M shares).
This table shows the top 264 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.